Symbols / ORIC
ORIC Chart
About
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.31B |
| Enterprise Value | 1.08B | Income | -129.47M | Sales | — |
| Book/sh | 3.90 | Cash/sh | 2.81 | Dividend Yield | — |
| Payout | 0.00% | Employees | 104 | IPO | — |
| P/E | — | Forward P/E | -8.59 | PEG | — |
| P/S | — | P/B | 3.46 | P/C | — |
| EV/EBITDA | -7.62 | EV/Sales | — | Quick Ratio | 13.79 |
| Current Ratio | 14.13 | Debt/Eq | 1.94 | LT Debt/Eq | — |
| EPS (ttm) | -1.71 | EPS next Y | -1.57 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-04 | ROA | -26.17% |
| ROE | -41.27% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 97.39M |
| Shs Float | 66.57M | Short Float | 22.98% | Short Ratio | 13.03 |
| Short Interest | — | 52W High | 14.93 | 52W Low | 3.90 |
| Beta | 1.33 | Avg Volume | 1.60M | Volume | 1.03M |
| Target Price | $21.23 | Recom | Strong_buy | Prev Close | $13.40 |
| Price | $13.50 | Change | 0.75% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.23
Mean price target
2. Current target
$13.50
Latest analyst target
3. DCF / Fair value
$-12.77
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.50
Low
$15.00
High
$25.00
Mean
$21.23
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | main | Citigroup | Buy → Buy | $17 |
| 2026-02-24 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2026-02-24 | reit | Wedbush | Outperform → Outperform | $20 |
| 2026-01-13 | reit | Wedbush | Outperform → Outperform | $20 |
| 2026-01-07 | init | Piper Sandler | — → Overweight | $22 |
| 2025-12-08 | main | Wells Fargo | Overweight → Overweight | $25 |
| 2025-12-08 | reit | Wedbush | Outperform → Outperform | $20 |
| 2025-11-20 | init | Evercore ISI Group | — → Outperform | $25 |
| 2025-11-18 | init | Wolfe Research | — → Peer Perform | — |
| 2025-11-18 | main | JP Morgan | Overweight → Overweight | $20 |
| 2025-11-17 | main | Citigroup | Buy → Buy | $16 |
| 2025-11-14 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-11-14 | main | Wells Fargo | Overweight → Overweight | $19 |
| 2025-11-14 | main | Oppenheimer | Outperform → Outperform | $15 |
| 2025-08-14 | main | JP Morgan | Overweight → Overweight | $17 |
| 2025-08-14 | main | HC Wainwright & Co. | Buy → Buy | $19 |
| 2025-08-13 | reit | Guggenheim | Buy → Buy | $18 |
| 2025-07-08 | init | Ladenburg Thalmann | — → Buy | $15 |
| 2025-05-19 | main | JP Morgan | Overweight → Overweight | $20 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $22 |
- Dominic Piscitelli Sells 52,000 Shares of Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat hu, 26 Feb 2026 23
- Oppenheimer reiterates Outperform on ORIC stock, $15 target - Investing.com ue, 24 Feb 2026 06
- $ORIC stock is up 11% today. Here's what we see in our data. - Quiver Quantitative ue, 24 Feb 2026 19
- Wall Street Analysts Believe Oric Pharmaceuticals (ORIC) Could Rally 58.43%: Here's is How to Trade - Nasdaq hu, 26 Feb 2026 14
- Insider Sell: Dominic Piscitelli Sells 52,000 Shares of ORIC Pha - GuruFocus Fri, 27 Feb 2026 00
- Trading the Move, Not the Narrative: (ORIC) Edition - Stock Traders Daily hu, 26 Feb 2026 14
- Oric Pharmaceuticals Launches New 2026 ATM Share Program - TipRanks Mon, 23 Feb 2026 22
- Assessing ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Data And US$264 Million Capital Raise - Yahoo Finance Wed, 25 Feb 2026 00
- A Look At ORIC Pharmaceuticals (ORIC) Valuation After Phase 1b Results And Extended Cash Runway - simplywall.st Wed, 25 Feb 2026 21
- ORIC Pharmaceuticals (NASDAQ: ORIC) boosts 2025 cash runway with $264M raise - Stock Titan Mon, 23 Feb 2026 21
- Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 85% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews Fri, 20 Feb 2026 15
- HC Wainwright Forecasts Strong Price Appreciation for Oric Pharmaceuticals (NASDAQ:ORIC) Stock - MarketBeat ue, 24 Feb 2026 16
- ORIC Pharmaceuticals Reports Promising Phase 1b Data for Rinzimetostat and Enozertinib, Completes $264 Million Funding Round - Quiver Quantitative Mon, 23 Feb 2026 21
- ORIC Pharmaceuticals (ORIC) Sees Price Target Raised to $25 by HC Wainwright & Co. | ORIC Stock News - GuruFocus ue, 24 Feb 2026 16
- Q1 EPS Forecast for Oric Pharmaceuticals Raised by Analyst - MarketBeat hu, 26 Feb 2026 12
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6700 | 80431.0 | — | Sale at price 12.00 per share. | HEYMAN RICHARD A | Director | — | 2026-01-16 00:00:00 | D/I |
| 1 | 10720 | 97127.0 | — | Sale at price 9.06 per share. | PISCITELLI DOMINIC G. | Chief Financial Officer | — | 2025-12-16 00:00:00 | D |
| 2 | 10720 | 97129.0 | — | Sale at price 9.06 per share. | MULTANI PRATIK S | Officer | — | 2025-12-16 00:00:00 | D |
| 3 | 33374 | 302368.0 | — | Sale at price 9.06 per share. | CHACKO JACOB M | Chief Executive Officer | — | 2025-12-16 00:00:00 | D |
| 4 | 29333 | nan | — | — | MULTANI PRATIK S | Officer | — | 2025-12-15 00:00:00 | D |
| 5 | 83666 | nan | — | — | CHACKO JACOB M | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 6 | 29333 | nan | — | — | PISCITELLI DOMINIC G. | Chief Financial Officer | — | 2025-12-15 00:00:00 | D |
| 7 | 10000 | 79000.0 | — | Conversion of Exercise of derivative security at price 7.90 per share. | KUNKEL LORI ANNE | Director | — | 2025-12-08 00:00:00 | D |
| 8 | 5534 | 20752.0 | — | Conversion of Exercise of derivative security at price 3.75 per share. | KUNKEL LORI ANNE | Director | — | 2025-12-04 00:00:00 | D |
| 9 | 11000 | 159719.0 | — | Sale at price 14.52 per share. | PISCITELLI DOMINIC G. | Chief Financial Officer | — | 2025-10-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -141.79M | -109.75M | -80.80M | -77.97M |
| TotalUnusualItems | 0.00 | -5.00M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -5.00M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -127.85M | -100.70M | -89.12M | -78.72M |
| ReconciledDepreciation | 1.11M | 1.03M | 966.00K | 897.00K |
| EBITDA | -141.79M | -109.75M | -85.80M | -77.97M |
| EBIT | -142.90M | -110.78M | -86.77M | -78.87M |
| NetInterestIncome | 2.65M | 141.00K | ||
| InterestIncome | 2.65M | 141.00K | ||
| NormalizedIncome | -127.85M | -100.70M | -84.12M | -78.72M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -127.85M | -100.70M | -89.12M | -78.72M |
| TotalExpenses | 142.90M | 110.78M | 86.77M | 78.87M |
| TotalOperatingIncomeAsReported | -142.90M | -110.78M | -91.77M | -78.87M |
| DilutedAverageShares | 69.73M | 51.45M | 39.66M | 37.95M |
| BasicAverageShares | 69.73M | 51.45M | 39.66M | 37.95M |
| DilutedEPS | -1.83 | -1.96 | -2.25 | -2.07 |
| BasicEPS | -1.83 | -1.96 | -2.25 | -2.07 |
| DilutedNIAvailtoComStockholders | -127.85M | -100.70M | -89.12M | -78.72M |
| NetIncomeCommonStockholders | -127.85M | -100.70M | -89.12M | -78.72M |
| NetIncome | -127.85M | -100.70M | -89.12M | -78.72M |
| NetIncomeIncludingNoncontrollingInterests | -127.85M | -100.70M | -89.12M | -78.72M |
| NetIncomeContinuousOperations | -127.85M | -100.70M | -89.12M | -78.72M |
| PretaxIncome | -127.85M | -100.70M | -89.12M | -78.72M |
| OtherIncomeExpense | 15.05M | 10.08M | -2.35M | 15.00K |
| OtherNonOperatingIncomeExpenses | 15.05M | 10.08M | 2.65M | 15.00K |
| SpecialIncomeCharges | 0.00 | -5.00M | 0.00 | |
| OtherSpecialCharges | 5.00M | |||
| NetNonOperatingInterestIncomeExpense | 2.65M | 141.00K | ||
| InterestIncomeNonOperating | 2.65M | 141.00K | ||
| OperatingIncome | -142.90M | -110.78M | -86.77M | -78.87M |
| OperatingExpense | 142.90M | 110.78M | 86.77M | 78.87M |
| ResearchAndDevelopment | 114.07M | 85.17M | 61.68M | 56.86M |
| SellingGeneralAndAdministration | 28.82M | 25.61M | 25.09M | 22.01M |
| GeneralAndAdministrativeExpense | 28.82M | 25.61M | 25.09M | 22.01M |
| OtherGandA | 28.82M | 25.61M | 25.09M | 22.01M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 71.02M | 54.87M | 45.09M | 39.43M |
| ShareIssued | 71.02M | 54.87M | 45.09M | 39.43M |
| TotalDebt | 3.18M | 2.75M | 2.66M | 1.93M |
| TangibleBookValue | 243.12M | 224.09M | 222.35M | 272.98M |
| InvestedCapital | 243.12M | 224.09M | 222.35M | 272.98M |
| WorkingCapital | 237.40M | 192.14M | 195.07M | 225.37M |
| NetTangibleAssets | 243.12M | 224.09M | 222.35M | 272.98M |
| CapitalLeaseObligations | 3.18M | 2.75M | 2.66M | 1.93M |
| CommonStockEquity | 243.12M | 224.09M | 222.35M | 272.98M |
| TotalCapitalization | 243.12M | 224.09M | 222.35M | 272.98M |
| TotalEquityGrossMinorityInterest | 243.12M | 224.09M | 222.35M | 272.98M |
| StockholdersEquity | 243.12M | 224.09M | 222.35M | 272.98M |
| GainsLossesNotAffectingRetainedEarnings | 379.00K | 258.00K | -1.29M | -103.00K |
| OtherEquityAdjustments | 379.00K | 258.00K | -1.29M | -103.00K |
| RetainedEarnings | -562.77M | -434.93M | -334.23M | -245.11M |
| AdditionalPaidInCapital | 805.51M | 658.75M | 557.87M | 518.18M |
| CapitalStock | 7.00K | 6.00K | 5.00K | 4.00K |
| CommonStock | 7.00K | 6.00K | 5.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 31.02M | 27.92M | 24.83M | 25.67M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.17M | 7.46M | 9.44M | 10.52M |
| OtherNonCurrentLiabilities | 6.17M | 7.46M | 9.44M | 10.52M |
| CurrentLiabilities | 24.85M | 20.46M | 15.39M | 15.15M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 3.18M | 2.75M | 2.66M | 1.93M |
| CurrentCapitalLeaseObligation | 3.18M | 2.75M | 2.66M | 1.93M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.65M | 6.53M | 5.32M | 4.80M |
| PayablesAndAccruedExpenses | 14.02M | 11.18M | 7.41M | 8.43M |
| CurrentAccruedExpenses | 12.47M | 10.23M | 6.09M | 6.54M |
| Payables | 1.55M | 944.00K | 1.32M | 1.89M |
| AccountsPayable | 1.55M | 944.00K | 1.32M | 1.89M |
| TotalAssets | 274.14M | 252.01M | 247.18M | 298.64M |
| TotalNonCurrentAssets | 11.89M | 39.41M | 36.72M | 58.12M |
| OtherNonCurrentAssets | 8.97M | 9.70M | 11.52M | 12.32M |
| InvestmentsAndAdvances | 0.00 | 26.85M | 21.95M | 43.39M |
| InvestmentinFinancialAssets | 0.00 | 26.85M | 21.95M | 43.39M |
| AvailableForSaleSecurities | 26.85M | 21.95M | 43.39M | |
| NetPPE | 2.92M | 2.86M | 3.25M | 2.41M |
| AccumulatedDepreciation | -7.48M | -6.49M | -5.79M | -4.99M |
| GrossPPE | 10.40M | 9.36M | 9.05M | 7.40M |
| Leases | 2.04M | 1.97M | 1.98M | 1.71M |
| OtherProperties | 7.39M | 6.60M | 6.25M | 5.30M |
| MachineryFurnitureEquipment | 971.00K | 793.00K | 819.00K | 387.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 262.25M | 212.60M | 210.46M | 240.52M |
| OtherCurrentAssets | 6.29M | 4.41M | 4.18M | 3.54M |
| PrepaidAssets | 3.54M | |||
| CashCashEquivalentsAndShortTermInvestments | 255.96M | 208.19M | 206.27M | 236.98M |
| OtherShortTermInvestments | 196.55M | 184.80M | 139.43M | 10.97M |
| CashAndCashEquivalents | 59.41M | 23.38M | 66.84M | 226.01M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -113.85M | -86.54M | -77.22M | -60.48M |
| IssuanceOfCapitalStock | 125.00M | 85.00M | 25.00M | 50.00M |
| CapitalExpenditure | -1.19M | -849.00K | -2.08M | -939.00K |
| EndCashPosition | 59.90M | 23.88M | 67.31M | 226.47M |
| BeginningCashPosition | 23.88M | 67.31M | 226.47M | 78.45M |
| ChangesInCash | 36.02M | -43.43M | -159.17M | 148.03M |
| FinancingCashFlow | 126.55M | 85.66M | 25.23M | 49.13M |
| CashFlowFromContinuingFinancingActivities | 126.55M | 85.66M | 25.23M | 49.13M |
| NetOtherFinancingCharges | -168.00K | -227.00K | -399.00K | -1.85M |
| ProceedsFromStockOptionExercised | 1.72M | 885.00K | 624.00K | 986.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 125.00M | 85.00M | 25.00M | 50.00M |
| CommonStockIssuance | 125.00M | 85.00M | 25.00M | 50.00M |
| InvestingCashFlow | 22.14M | -43.40M | -109.25M | 158.44M |
| CashFlowFromContinuingInvestingActivities | 22.14M | -43.40M | -109.25M | 158.44M |
| NetInvestmentPurchaseAndSale | 23.32M | -42.55M | -107.17M | 159.37M |
| SaleOfInvestment | 275.25M | 196.69M | 130.95M | 229.00M |
| PurchaseOfInvestment | -251.92M | -239.24M | -238.12M | -69.63M |
| NetPPEPurchaseAndSale | -1.19M | -849.00K | -2.08M | -939.00K |
| PurchaseOfPPE | -1.19M | -849.00K | -2.08M | -939.00K |
| OperatingCashFlow | -112.66M | -85.69M | -75.14M | -59.54M |
| CashFlowFromContinuingOperatingActivities | -112.66M | -85.69M | -75.14M | -59.54M |
| ChangeInWorkingCapital | 1.97M | 4.90M | -445.00K | 4.07M |
| ChangeInPayablesAndAccruedExpense | 1.82M | 3.28M | -1.48M | 2.93M |
| ChangeInPayable | 2.93M | |||
| ChangeInAccountPayable | 2.93M | |||
| ChangeInPrepaidAssets | 143.00K | 1.62M | 1.03M | 1.14M |
| StockBasedCompensation | 20.21M | 15.23M | 14.46M | 12.85M |
| AmortizationOfSecurities | -8.10M | -6.17M | -1.04M | 1.35M |
| DepreciationAmortizationDepletion | 1.11M | 1.03M | 966.00K | 897.00K |
| DepreciationAndAmortization | 1.11M | 1.03M | 966.00K | 897.00K |
| Depreciation | 1.11M | 1.03M | 966.00K | 897.00K |
| OperatingGainsLosses | 22.00K | 40.00K | 2.00K | |
| GainLossOnSaleOfPPE | 0.00 | 22.00K | 40.00K | 2.00K |
| NetIncomeFromContinuingOperations | -127.85M | -100.70M | -89.12M | -78.72M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ORIC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|